Status:
UNKNOWN
Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Severe Sepsis
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The objective of this pilot study is to estimate a procedure where the biological samples routinely obtained at the site of suspected infection could be guided by the early realization of a TEP with F...
Detailed Description
Severe sepsis constitutes the leading cause of mortality in ICU, in particular because a microbial documentation is lacking in about half of the cases. Tomography by emission of positons, which uses ...
Eligibility Criteria
Inclusion
- Patient hospitalized with severe sepsis
- Absence of infected site clearly identified after 48 hours of a conventional diagnosis assessment or suspicion of one or more additional sites
- Indication of scanner X with injection
- Informed consent obtained
Exclusion
- Age over 80
- Immunocompromised status
- Surgical intervention within the previous month
- Hemodynamic instability (defined by the use of more than 0.5µg/kg/min vasopressors)
- Severe hypoxia (defined by a PaO2/FiO2 ratio lower than 150)
- Pregnancy
- Patient already included in another protocol
- Anaphylaxis to Flucis
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00791310
Start Date
November 1 2008
End Date
October 1 2010
Last Update
December 31 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU; Central Hospital
Nancy, France, 54000